RTI-31

RTI-31 (also known as 3β-(4-Chlorophenyl)-2β-[3-(4'-methylphenyl)isoxazol-5-yl]tropane or RTI-4229-31) is a synthetic compound of the phenyltropane class. It is a potent and selective dopamine reuptake inhibitor (DRI) and is derived from methylecgonidine. RTI-31 is notable for its high binding affinity to the dopamine transporter (DAT).

Chemistry

RTI-31 belongs to the phenyltropane class of compounds, which are tropane derivatives. The tropane ring of RTI-31 is substituted at the 2β and 3β positions. The 2β position is substituted with an isoxazole ring, which is in turn substituted at the 3 position with a 4'-methylphenyl group. The 3β position is substituted with a 4-chlorophenyl group.

Pharmacology

RTI-31 acts as a potent and selective dopamine reuptake inhibitor. It binds to the dopamine transporter (DAT) with high affinity, thereby blocking the reuptake of dopamine and increasing its extracellular concentrations. This results in increased dopaminergic neurotransmission, which is associated with effects such as increased alertness, increased locomotor activity, and euphoria.

Research and Development

RTI-31 was developed as part of the RTI series of compounds, a series of phenyltropane derivatives that were designed to be potent inhibitors of the dopamine transporter. The RTI series was developed by the Research Triangle Institute (RTI), and RTI-31 is one of the most potent compounds in this series.

See Also

• RTI-55
• RTI-113
• RTI-336
• Phenyltropane